(Q28189439)

Stefan Faderl

0 references

Jorge Eduardo Cortes

Jorge Cortes

0 references

Susan O'Brien

Susan O'Brien

0 references

Mary Beth Rios

Mary Beth Rios

0 references

Guillermo Garcia-Manero

Guillermo Garcia-Manero

0 references

Michael Andreeff

Michael Andreeff

0 references

Michael J. Keating

Michael Keating

0 references

Jean-Pierre J Issa

Jean-Pierre Issa

0 references

Jianqin Shan

Jianqin Shan

0 references

Moshe Talpaz

Moshe Talpaz

0 references

Francis J Giles

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Francis J Giles

0 references

language of work or name

English

0 references

publication date

1 August 2003

0 references

0 references

0 references

0 references

522-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11543

7 January 2021